## Highlights of This Issue 1125

**REVIEW**

1127  
**Novel Therapeutic Options in Anaplastic Large Cell Lymphoma: Molecular Targets and Immunological Tools**  
Olaf Merkel, Frank Hamacher, Eveline Sifft, Lukas Kenner, and Richard Greil  
for the European Research Initiative on Anaplastic Large Cell Lymphoma

1194  
**Hsp90 Inhibitor–Mediated Disruption of Chaperone Association of ATR with Hsp90 Sensitizes Cancer Cells to DNA Damage**  

**THERAPEUTIC DISCOVERY**

1137  
**Expression Signatures of the Lipid-Based Akt Inhibitors Phosphatidylinositol Ether Lipid Analogues in NSCLC Cells**  
Chunyu Zhang, Abdel G. Elkahloun, Hongling Liao, Shannon Delaney, Barbara Saber, Betsy Morrow, George C. Prendergast, M. Christine Holland, Joell J. Gill, and Phillip A. Dennis

1207  
**Silencing IL-13Rα2 Promotes Glioblastoma Cell Death via Endogenous Signaling**  
Linda C. Hsi, Suman Kundu, Juan Palomo, Bo Xu, Ryan Ficco, Michael A. Vogelbaum, and Martha K. Cathcart

1161  
**Cannabidiol Induces Programmed Cell Death in Breast Cancer Cells by Coordinating the Cross-talk between Apoptosis and Autophagy**  
Ashutosh Shirivastava, Paula M. Kuzzontkoski, Jerome E. Groopman, and Anil Prasad

1218  
**E7080 Suppresses Hematogenous Multiple Organ Metastases of Lung Cancer Cells with Nonmutated Epidermal Growth Factor Receptor**  

**PRECLINICAL DEVELOPMENT**

1173  
**Time-Course Imaging of Therapeutic Functional Tumor Vascular Normalization by Antiangiogenic Agents**  
Qingbei Zhang, Vytaus Bindokas, Jikun Shen, Hanli Fan, Robert M. Hoffman, and H. Rosie Xing

1229  
**Characterization of the Oncogenic Activity of the Novel TRIM59 Gene in Mouse Cancer Models**  
Fatma Vallyeva, Fei Jiang, Ahmed Elmaadawi, Madeleine Moussa, Siu-Pok Yue, Leda Raptis, Jonathan I. Izawa, Burton B. Yang, Norman M. Greenberg, Fen Wang, and Jim W. Xuan

Response of Human Prostate Cancer Cells and Tumors to Combining PARP Inhibition with Ionizing Radiation  
Sorafenib Enhances the Antitumor Effects of Chemoradiation Treatment by Downregulating ERCC-1 and XRCC-1 DNA Repair Proteins
Arti Yadav, Bhavna Kumar, Theodoros N. Teknos, and Pawan Kumar

Novel Acrylonitrile Derivatives, YHO-13177 and YHO-13351, Reverse BCRP/ABCG2-Mediated Drug Resistance In Vitro and In Vivo
Ryuta Yamazaki, Yukiko Nishiyama, Tomio Furuta, Hiroshi Hatano, Yoshiaki Igarashi, Naoyuki Asakawa, Hiroshi Kodaira, Hiroyuki Takahashi, Ritsuo Aiyama, Takeshi Matsuzaki, Nao Yagi, and Yoshikazu Sugimoto

Synergistic Antitumor Activity of Gemcitabine and ABT-737 In Vitro and In Vivo through Disrupting the Interaction of USP9X and Mcl-1
Chong Zhang, Tian-yu Cai, Hong Zhu, Liu-qing Yang, Hai Jiang, Xiao-wu Dong, Yong-zhou Hu, Neng-ming Lin, Qiao-jun He, and Bo Yang

Development and Characterization of a Potent Immunoconjugate Targeting the Fn14 Receptor on Solid Tumor Cells
Hong Zhou, John W. Marks, Walter N. Hittelman, Hideo Yagita, Lawrence H. Cheung, Michael G. Rosenblum, and Jeffrey A. Winkles

Chemotherapy Dosing Schedule Influences Drug Resistance Development in Ovarian Cancer
Raquel De Souza, Payam Zahedi, Rose M. Badame, Christine Allen, and Micheline Piquette-Miller

Phase I Trial of Hepatic Arterial Infusion of Nanoparticle Albumin–Bound Paclitaxel: Toxicity, Pharmacokinetics, and Activity
Siqing Fu, Aung Naing, Stacy L. Moulder, Kirk S. Culotta, David C. Madoff, Chaan S. Ng, Timothy L. Madden, Gerald S. Falchook, David S. Hong, and Razelle Kurzrock

About the Cover
A novel TRIM family member TRIM59 has proto-oncogenic activity in a transgenic mouse prostate cancer modeling test. Restricted TRIM59 gene expression in the mouse prostate using a prostate tissue-specific gene (PSP94) revealed the full potential for tumorigenesis and developed poorly differentiated cancer of the prostate and comedocarcinoma, which had features of neurocarcinoma (small cell carcinoma) and central necrosis. The PSP94-TRIM59 mice coincided with the upregulation of genes specific to the Ras signaling pathway and bridging genes for SV40Tag-mediated oncogenesis. For details, see the article by Valiyeva and colleagues on page 1229.
Molecular Cancer Therapeutics

10 (7)


Updated version  Access the most recent version of this article at:
http://mct.aacrjournals.org/content/10/7

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.
Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.
Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.